A multiple-ascending dose trial evaluating NKTR-358 in patients with systemic lupus erythematosus (SLE)
Phase of Trial: Phase I/II
Latest Information Update: 01 Mar 2018
At a glance
- Drugs NKTR 358 (Primary)
- Indications Systemic lupus erythematosus
- Focus Therapeutic Use
- 01 Mar 2018 According to a Nektar Therapeutics media release, company plans to initiate this trial in the second quarter of 2018.
- 30 Mar 2017 New trial record
- 27 Mar 2017 According to a Nektar Therapeutics media release, company plans to initiate this trial in second half of 2017.